Results of RCTs comparing FDG-PET scanning to direct therapy
| Trial . | Intervention control participants . | OS, % . | FFTF, % . | PFS, % . | EFS, % . | Late AE, % . | Response, % . | Median follow-up . | Reference . |
|---|---|---|---|---|---|---|---|---|---|
| EORTC/LYSA/ FIL H10 (favorable) | Arm A (control) (n = 223): 3 × ABVD + 30-Gy INRT (FDG-PET completed only for comparison in control arm) Arm B (intervention) (n = 221): 2 × ABVD + FDG-PET If FDG-PET negative: 2 × ABVD and no radiotherapy If FDG-PET positive: 2 × BEACOPP + 30-Gy INRT | NR | NR | *100 vs 94.9 at 1 y | NR | NR | NR | 1.1 y | 17, 27 |
| EORTC/LYSA/ FIL H10 (unfavorable) | Arm A (control) (n = 346): 4 × ABVD + 30-Gy INRT (FDG-PET completed only for comparison) Arm B (intervention) (n = 347): 2 × ABVD + FDG-PET If FDG-PET negative: 4 × ABVD If FDG-PET positive: 2 × BEACOPP + 30-Gy INRT | NR | NR | *97.3 vs 94.7 at 1y | NR | NR | NR | 1.1 y | 17, 27 |
| RAPID | 3 × ABVD + FDG-PET If FDG-PET negative: Arm A: IFRT (n = 209) Arm B: no further intervention (n = 211) If FDG-PET positive: 1 × ABVD + IFRT | 97 vs 99.5 at 3 y (P values NR) | NR | *93.8 vs 90.7 at 3 y (risk difference of 2.9%; 95% CI: −10.7 to 1.4 (this exceeds the margin for noninferiority of −7%) | NR | NR | NR | 48 mo | 18 |
| Trial . | Intervention control participants . | OS, % . | FFTF, % . | PFS, % . | EFS, % . | Late AE, % . | Response, % . | Median follow-up . | Reference . |
|---|---|---|---|---|---|---|---|---|---|
| EORTC/LYSA/ FIL H10 (favorable) | Arm A (control) (n = 223): 3 × ABVD + 30-Gy INRT (FDG-PET completed only for comparison in control arm) Arm B (intervention) (n = 221): 2 × ABVD + FDG-PET If FDG-PET negative: 2 × ABVD and no radiotherapy If FDG-PET positive: 2 × BEACOPP + 30-Gy INRT | NR | NR | *100 vs 94.9 at 1 y | NR | NR | NR | 1.1 y | 17, 27 |
| EORTC/LYSA/ FIL H10 (unfavorable) | Arm A (control) (n = 346): 4 × ABVD + 30-Gy INRT (FDG-PET completed only for comparison) Arm B (intervention) (n = 347): 2 × ABVD + FDG-PET If FDG-PET negative: 4 × ABVD If FDG-PET positive: 2 × BEACOPP + 30-Gy INRT | NR | NR | *97.3 vs 94.7 at 1y | NR | NR | NR | 1.1 y | 17, 27 |
| RAPID | 3 × ABVD + FDG-PET If FDG-PET negative: Arm A: IFRT (n = 209) Arm B: no further intervention (n = 211) If FDG-PET positive: 1 × ABVD + IFRT | 97 vs 99.5 at 3 y (P values NR) | NR | *93.8 vs 90.7 at 3 y (risk difference of 2.9%; 95% CI: −10.7 to 1.4 (this exceeds the margin for noninferiority of −7%) | NR | NR | NR | 48 mo | 18 |
RAPID, PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma.
Primary outcome.